TABLE 2.
Adjusted risk analysis for the risk of nephrosclerosis.
| Gene | SNP | Genotype | Control, n (%) | CKD, n (%) | OR | p-value |
|---|---|---|---|---|---|---|
| SCARB1 | rs838880 | T/T | 314 (45.5) | 235 (49.5) | 0.66 (0.51–0.87) | 0.003 |
| T/C-C/C | 376 (54.5) | 240 (50.5) | ||||
| SCARB1 | rs10846744 | G/G | 460 (66.7) | 285 (60.3) | 1.48 (1.11–1.96) | 0.007 |
| G/C-C/C | 230 (33.3) | 188 (39.7) | ||||
| PLA2G4A | rs78178583 | A/A | 611 (85.7) | 401 (82.2) | 1.58 (1.09–2.29) | 0.015 |
| A/C-C/C | 102 (14.3) | 87 (17.8) | ||||
| PLA2G4A | rs72709847 | T/T | 575 (80.8) | 413 (84.8) | 0.70 (0.49–0.99) | 0.046 |
| T/A-A/A | 137 (19.2) | 74 (15.2) | ||||
| PLA2G4A | rs1569479 | T/T | 153 (22.1) | 133 (28.1) | 0.73 (0.53–1) | 0.048 |
| T/G-G/G | 538 (77.9) | 340 (71.9) |
CKD, nephrosclerosis patients; OR, odds ratios with 95% confidence interval.